Search

Displaying results 8441 - 8450 of 10000 in total
  1. Drug

    CEP-9722

    go.drugbank.com/drugs/DB14882
    Investigational

    CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).

    Categories: Heterocyclic Compounds, 2-Ring, Heterocyclic Compounds, 3-Ring
  2. Drug

    Lorecivivint

    go.drugbank.com/drugs/DB14883
    Investigational

    Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  3. Drug

    PF-05180999

    go.drugbank.com/drugs/DB14885
    Investigational

    PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).

  4. Drug

    Vobarilizumab

    go.drugbank.com/drugs/DB14891
    Investigational

    Vobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).

  5. Drug

    Galicaftor

    go.drugbank.com/drugs/DB14894
    Investigational

    Galicaftor is under investigation in clinical trial NCT03540524 (A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  6. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. … [L28310] Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012.

    Categories: Adrenergic beta-3 Receptor Agonists, Cytochrome P-450 Substrates
  7. Drug

    ISO-1 F-18

    go.drugbank.com/drugs/DB14900
    Investigational

    ISO-1 F-18 is under investigation in clinical trial NCT00968656 (Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1).

    Synonyms: F-18-ISO, [18F]ISO-1
  8. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    Inclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density … lipoprotein cholesterol (LDL-C) levels.

    Categories: Compounds used in a research, industrial, or household setting, Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsProducts: LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  9. Drug

    Emactuzumab

    go.drugbank.com/drugs/DB14905
    Investigational

    Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).

  10. Drug

    Bevacizumab zirconium Zr-89

    go.drugbank.com/drugs/DB14907
    Investigational

    Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).

    Categories: Compounds used in a research, industrial, or household setting